To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Bill 117 hr 6832, also known as the "State Access to Therapies Act," aims to amend two important acts, the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950. The main goal of this bill is to prevent the Federal Government from restricting State access to crucial therapies, specifically monoclonal antibodies, and from giving priority to Federal contracts over State contracts when purchasing supplies to combat the COVID-19 pandemic.

The bill seeks to ensure that States have equal access to key therapies, such as monoclonal antibodies, which have been proven to be effective in treating COVID-19. By prohibiting the Federal Government from limiting State access to these therapies, the bill aims to ensure that all States have the resources they need to effectively combat the pandemic.

Additionally, the bill aims to prevent the Federal Government from prioritizing Federal contracts over State contracts when purchasing supplies to combat COVID-19. This provision is intended to ensure that States are not disadvantaged in their efforts to procure essential supplies, such as personal protective equipment and testing kits, needed to combat the pandemic. Overall, the State Access to Therapies Act is designed to promote fairness and equity in the distribution of resources to combat COVID-19, by ensuring that States have equal access to key therapies and supplies needed to effectively respond to the pandemic.